Risks of Rapid Dose Escalation Speeding up dose escalation may seem beneficial at first, especially when patients experience quick weight loss or improved glucose control with GLP-1 therapy
Given these concerns, the JDS has issued the "Recommendations for Safe Use of Incretin-Based Therapies, Second Edition" (Table 1) [13] emphasizing that careful consideration of hypoglycemia risk, remaining -cell function and mass, gastrointestinal side effects is essential when determining tirzepatide indications and treatment continuation
Every protocol is tailored to your medical history, goals, and response
The latter differentiation depends on the sustained ability of short-acting GLP-1 receptor agonists to delay gastric emptying by inhibiting gastric motility, as tachyphylaxia of this effect appears after long-term GLP-1 receptor agonism [3]
received honoraria for speaking at meetings for Roche and Novo Nordisk
S., Skeie, G